How Biotech Founders Raise More With a Stronger Online Presence

You’ve spent years building something real. Maybe it’s a novel drug delivery platform, a diagnostic tool that catches disease earlier than anything on the market, or a gene therapy that could change lives. The science is solid. The team is credible. The data is promising.

And yet — when a tier-one life sciences investor Googles your company before your first call, what do they find?

A half-finished website. A LinkedIn page with 47 followers. A founder profile that hasn’t been updated since 2021. Maybe a press release your PR firm pushed out 18 months ago that ranks on page three.

This is the gap that costs biotech founders real money. Not because investors are superficial — but because in a world where they’re evaluating hundreds of companies a year, your digital presence is your first impression, your credibility signal, and your competitive moat all rolled into one.

Let’s talk about why this matters more than most founders think, and what you can actually do about it.

The Painful Truth: Investors Research You Before You Know They Exist

Here’s a scenario most biotech founders don’t account for.

An analyst at a health-focused venture fund is building a landscape map of companies working in your therapeutic area. They’re not waiting for a warm intro. They’re not sitting in your pitch deck queue. They’re on Google, on PubMed, on LinkedIn, and on Crunchbase — quietly building a list of companies worth tracking.

If your online presence is weak, you don’t get on that list. You’re invisible.

By the time you’re ready to launch your Series A, that analyst has already formed a mental shortlist. The companies they’ve been following for six months — watching their progress, reading their founder’s posts, tracking their scientific milestones — those are the companies that get the first call. The companies that are easy to find, easy to understand, and easy to trust.

You can have the best science in the room and still lose the deal at the Google search stage.

This isn’t a small problem. The average institutional investor reviews thousands of companies annually and makes a handful of investments. Anything that makes you harder to find, harder to understand, or harder to believe in is a filter that works against you — often before you’ve said a single word.

Why Biotech Founders Deprioritize This (And Why That’s a Mistake)

Look, you’re not lazy. You’re stretched thin.

Between managing your CRO relationships, preparing for your IND filing, keeping your board happy, and recruiting for three open positions, “build a content strategy” doesn’t exactly feel urgent. Digital marketing sounds like something consumer brands do, not companies developing novel therapeutics.

There’s also an underlying assumption many science-first founders carry: that the data should speak for itself. If the science is good enough, the right investors will find you. If the efficacy signals are strong, no one’s going to care what your website looks like.

This assumption has a grain of truth in a world where you have unlimited warm intros, a famous advisor on speed dial, and a co-founder who went to Harvard Med with half the partners at top-tier biotech funds.

For everyone else — which is most founders — it’s a costly misconception.

The reality is that investors are pattern-matching constantly. And your online presence is one of the most powerful pattern-matching signals they have access to before meeting you. A polished, substantive, scientifically credible online presence signals that you understand your audience, you communicate well, and you’re building something worth paying attention to. A weak one signals the opposite, even if it’s not true.

What “Online Presence” Actually Means for a Biotech Startup

Let’s get specific, because “online presence” can feel vague and overwhelming.

For a biotech startup preparing for a capital raise, online presence comes down to five core pillars.

Your website

This is your home base. It needs to communicate what you do, why it matters, and why your team is uniquely positioned to do it — in plain language, without dumbing down the science. Investors aren’t all MDs. Your website needs to work for the generalist partner AND the scientific advisor doing diligence. Most biotech websites fail at this because they’re either too jargon-heavy or too vague. Both are death.

Your founder and leadership LinkedIn profiles

Before an investor takes a meeting with your company, they’ll almost certainly look up the CEO and the CSO on LinkedIn. These profiles need to tell a coherent, compelling story about your credibility and your journey to this moment. Not a resume dump. A narrative.

Your company’s LinkedIn page

This is where you demonstrate that you’re active, you’re making progress, and you know how to communicate your science. Regular, thoughtful posts here build the kind of ambient awareness that makes investors feel like they already know you before you ask for a meeting.

Your media and publication footprint

Have you published? Have you been quoted in STAT News, Fierce Biotech, or BioPharma Dive? Have you spoken at JPMorgan, BIO, or ASCO? This kind of third-party credibility is enormously powerful. If you haven’t started building it yet, you need to start now — because it takes time.

Your search presence

When someone Googles your company name, your therapeutic area, or your technology platform, what comes up? Ideally, you want a mix of your own properties and third-party coverage that tells a coherent, credible story. If nothing comes up, or if what comes up is outdated or confusing, that’s a problem.

The SEO Angle Nobody Talks About in Biotech

SEO — search engine optimization — sounds like something e-commerce companies worry about. Ranking for keywords, driving traffic, conversion funnels. None of that feels relevant to a pre-revenue biotech with 12 employees.

But there’s a version of SEO that’s deeply relevant to your fundraising strategy, and it’s not about driving consumer traffic. It’s about controlling your narrative online.

Think about the searches an investor might run before your meeting:

• Your company name
• Your lead compound or platform technology
• The disease area you’re targeting
• Your co-founder’s name
• The clinical problem you’re solving

If your website and content aren’t optimized to show up clearly for these searches, you’re leaving your narrative in someone else’s hands. What ranks instead? Maybe a competitor. Maybe an outdated press release. Maybe nothing at all, which is almost worse.

Biotech-specific SEO doesn’t require gaming algorithms. It requires publishing clear, substantive content about your science and your company — consistently, over time — in a format that search engines can index and rank. That means a well-structured website, blog posts or pipeline updates written in plain English, and metadata that actually describes what you do.

The compounding effect of this over 12 to 18 months is significant. Founders who start this early — ideally well before their next fundraise — show up in investor searches at the exact moment investors are forming their shortlists.

How Online Presence Directly Impacts Capital Raising

Let’s get concrete about the mechanics here, because this isn’t theoretical.

It shortens your fundraising timeline

The longer investors spend trying to understand your company from scratch during diligence, the longer your round takes. A clear, well-documented online presence answers basic questions before they’re even asked. It means your first conversation can be about conviction, not context-setting.

It improves your inbound deal flow

The best investors aren’t always the ones you chase. Some of the most valuable checks come from investors who found you, liked what they saw, and reached out. That only happens if there’s something to find.

It creates social proof

Investors talk to each other. When one partner mentions your company to a colleague, the first thing that colleague does is Google you. If what they find is impressive, you’ve just amplified your reach through a channel you didn’t have to pay for.

It signals operational seriousness

This one surprises founders, but it’s real. Investors use your digital presence as a proxy for how you operate. A company with a thoughtful, well-maintained website and active, credible founders on LinkedIn signals that leadership pays attention to detail and thinks about external communication. That matters more than you’d expect.

It keeps you top of mind between touchpoints

Most investor relationships take months or years to convert into checks. During that time, your content — posts, updates, milestones, scientific commentary — is doing the relationship-maintenance work that you can’t do personally at scale.

The Founder’s Personal Brand Problem Nobody Wants to Admit

Here’s an uncomfortable truth: investors often bet on founders as much as they bet on science.

In early-stage biotech especially, where clinical outcomes are years away and uncertainty is enormous, the question “do I believe in this person?” carries enormous weight. Your personal credibility — your track record, your scientific depth, your ability to attract talent and partnerships — is a huge part of what’s being underwritten.

Your personal online presence is where that credibility lives digitally.

A founder who publishes thoughtful commentary on their therapeutic area, who engages publicly with the scientific literature, who shares company milestones and communicates the “why” behind their work — that founder is building trust at scale, with people they’ve never met, every single day.

A founder who is essentially invisible online is missing this entirely.

You don’t need to become a LinkedIn influencer. You don’t need to post every day or build a personal newsletter or get on every podcast. But you do need a visible, coherent, credible digital presence that tells the story of who you are, why you started this company, and why you’re the right person to see it through.

This is especially critical for first-time founders. If you don’t have a famous lab behind you or a previous exit on your bio, your online presence is one of the few tools you have to build credibility with investors who don’t already know you.

Practical Steps to Start Elevating Your Online Presence Now

This doesn’t have to be an overwhelming overhaul. Here’s how to approach it in phases.

Phase one: Fix the foundation

Audit your company website against this simple test — can a smart non-scientist understand what you do, why it matters, who you are, and what stage you’re at in under two minutes? If not, that’s your first priority. Update your leadership team bios. Make sure your pipeline page is current. Add a news or updates section if you don’t have one.

Phase two: Optimize your LinkedIn footprint

Rewrite your personal LinkedIn summary as a narrative, not a CV. Connect with investors, journalists, KOLs, and peers in your therapeutic area. Start posting — even once or twice a week — about your science, your milestones, and your perspective on the field. Do the same for your company page.

Phase three: Build your publication and media presence

Pitch a contributed article to a trade publication. Reach out to journalists covering your disease area with a useful data point or perspective, not a press release. Apply to speak at a relevant conference. These take time, but each one compounds.

Phase four: Create content that ranks

Work with someone who understands both biotech and SEO to develop content that answers the questions investors and partners are actually searching for. Pipeline explainers. Disease area overviews. Platform technology breakdowns. This is long-game work, but it pays dividends for years.

Phase five: Build a cadence and stick to it

Online presence isn’t a one-time project. It’s a system. Set a sustainable rhythm — one LinkedIn post per week, one company update per month, one media placement per quarter — and maintain it consistently. Consistency beats intensity every time.

Timing: When Should You Start?

Yesterday.

But realistically, the right time to start building your online presence is at least 12 to 18 months before you expect to be actively fundraising.

Here’s why the timeline matters.

Content takes time to index and rank. Relationship awareness with investors takes time to build. Credibility on LinkedIn compounds over months, not days. If you launch a Series B process and simultaneously try to build your online presence from scratch, you’re fighting two battles at once — and you’ll be behind on both.

The founders who raise the fastest and at the best terms are almost always the ones who have been visible, credible, and findable for the 12 months leading up to their round. By the time they’re actively pitching, investors already know who they are. The pitch is a formality, not an introduction.

Start now. Even imperfectly. A mediocre LinkedIn post published today is infinitely more valuable than a perfect content strategy that’s still being planned six months from now.

The Competitive Angle You Can’t Ignore

Here’s something worth sitting with.

Your competitors are reading this too. And some of them are already doing it.

The biotech founder who has been posting thoughtful content about their approach to CNS drug delivery for the past 18 months already has a relationship with investors who follow that topic. The startup that published a clear, accessible explainer of their platform technology on their website six months ago is already ranking when investors search that category.

Online presence is one of the few areas in biotech fundraising where first-mover advantage is genuinely real and genuinely accessible. You don’t need a bigger budget. You don’t need a famous co-founder. You need consistency, clarity, and the willingness to show up — publicly, credibly, and regularly — while your competitors are heads-down in the lab, assuming the science will do the talking.

The science matters enormously. But the science needs an audience.

Final Thought: This Is Infrastructure, Not Marketing

The mental shift that helps most founders is this: stop thinking about your online presence as marketing, and start thinking about it as infrastructure.

Your CRM is infrastructure. Your data room is infrastructure. Your IP portfolio is infrastructure. These are assets that make your company more fundable, more credible, and more valuable over time.

Your online presence is exactly the same kind of asset. Built carefully, maintained consistently, and aligned with your fundraising strategy, it’s one of the highest-ROI investments you can make as a founder — not because it feels good, but because it quietly and powerfully determines whether the right investors find you, trust you, and ultimately back you.

The founders who understand this raise faster, raise better, and spend less time cold-pitching into the void.

The ones who don’t are still waiting for the science to speak for itself.

Building your biotech’s online presence is a long game — but it’s one of the few games where starting early creates a durable, compounding advantage. If you’re preparing for a capital raise in the next 12 to 24 months, now is the right time to begin.

Ready to Make Investors Find You First?

If you’re a biotech, medtech, diagnostics, and healthcare founder preparing for your next raise in the next 12 to 24 months, I help you build the digital presence and investor outreach strategy that puts you in front of the right people — before you ever send a cold email.

As a Founder Visibility & Investor Outreach Strategist, I work exclusively with biotech and life sciences founders to close the gap between great science and investor awareness.

If this article resonated, let’s talk. Book a free discovery call and we’ll map out exactly where your online presence stands today — and what it needs to look like before your next round.

[Book Your Free Discovery Call →]